Mureva Announces FDA De Novo Authorization and Peer-Reviewed Publication of Pivotal Mureva OM Trial
RegulatoryapprovedMureva OMPositive
AI Analysis
Summary
Mureva Phototherapy received FDA De Novo authorization for Mureva OM to treat severe oral mucositis, supported by a randomized, sham-controlled pivotal trial. The company also published peer-reviewed results from the Mureva OM trial.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
FDA granted De Novo authorization for Mureva OM
Importance:8/10
Sentiment:
0.90
FDA approvalDe Novo authorizationoral mucositisphototherapyclinical trialpeer-reviewed publication
Read the original article
Published by PR Newswire Biotech on September 10, 2026 1:00 PM